Liver Research, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Gastroenterology, Год журнала: 2024, Номер 167(4), С. 689 - 703
Опубликована: Апрель 29, 2024
Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC preventable with about 70% attributable to modifiable risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), Food and Drug Administration-approved medications for treating type 2 diabetes mellitus (T2DM), have pleiotropic effects on counteracting factors HCC. Here we evaluate the association GLP-1RAs incident in real-world population.
Язык: Английский
Процитировано
41
Journal of clinical lipidology, Год журнала: 2024, Номер 18(3), С. e320 - e350
Опубликована: Апрель 24, 2024
BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.
Язык: Английский
Процитировано
30
Liver International, Год журнала: 2024, Номер 44(10), С. 2538 - 2550
Опубликована: Июль 1, 2024
We examined the impact of a co-diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.
Язык: Английский
Процитировано
21
Nutrients, Год журнала: 2024, Номер 16(14), С. 2220 - 2220
Опубликована: Июль 11, 2024
Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.
Язык: Английский
Процитировано
20
Obesity Pillars, Год журнала: 2024, Номер 10, С. 100108 - 100108
Опубликована: Март 12, 2024
This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.
Язык: Английский
Процитировано
19
Frontiers in Endocrinology, Год журнала: 2024, Номер 15
Опубликована: Май 8, 2024
Background The estimated glucose disposal rate (eGDR), an effective indicator of insulin resistance, has been related to acute coronary syndrome, ischemic stroke and heart failure. This study aims explore the relationship between eGDR arterial stiffness, all-cause mortality cardiovascular in patients with non-alcoholic fatty liver disease (NAFLD). Methods Participants NAFLD were chosen from National Health Nutrition Examination Survey (NHANES) 1999 2018. main outcomes are stiffness (represented by pulse wave velocity, ePWV), mortality. Multiple cox regression models, restricted cubic spline, sensitivity analysis subgroup carried out investigate correlation resistance indicators stiffness. Furthermore, receiver operating characteristic curves used compare predictive value triglyceride-glucose (TyG) index homeostasis model assessment (HOMA-IR) for Results In this study, a total 4,861 participants included analysis. After adjusting confounding factors multivariate weighted model, was inversely associated (Q4 vs. Q1, HR =0.65 (0.48-0.89, P=0.01) =0.35 (0.19-0.65, P<0.001). Compared TyG HOMA-IR, shows excellent (0.588 0.550 0.513, P < 0.001) (0.625 0.553 0.537, 0.001). addition, we found significant negative (β=-0.13(-0.14–0.11, P< However, HOMA-IR showed no Conclusions Low (an resistance) levels increased risk United States.
Язык: Английский
Процитировано
18
Current Obesity Reports, Год журнала: 2025, Номер 14(1)
Опубликована: Янв. 11, 2025
This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.
Язык: Английский
Процитировано
11
Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown
Опубликована: Фев. 18, 2025
ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. global prevalence diseases, including diabetes, chronic liver disease, cardiometabolic disease kidney has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic (MASLD), formerly known as non‐alcoholic fatty is leading cause worldwide. MASLD poses significant health challenge with its rising prevalence, placing substantial burden on healthcare systems, impacts patient well‐being incurs economic costs. Addressing requires comprehensive understanding interconnected factors, implications. Lack awareness, imprecise non‐invasive diagnostic methods ineffective preventive interventions are core components the MASLD‐related problem. Aim aim this article was summarise from payer's perspective. Methods We carried out review MASLD. These topics led discussions insights by an expert panel during 7th Continuum Roundtable meeting, which took place November 2023. This meeting focused burden, patient‐reported outcomes economics, payor societal perspectives, aimed identify opportunities for improving care, optimise resource allocation mitigate overall impact individuals society related During roundtable, emphasis emerged need greater awareness strategic deployment diagnostic, therapeutic preventative measures address effectively. Conclusion high growing. Prioritising prevention dysregulation timely can yield holistic strategy combat MASLD, progression potentially lower Trial Registration: NCT06309992
Язык: Английский
Процитировано
4
Diagnostics, Год журнала: 2025, Номер 15(3), С. 252 - 252
Опубликована: Янв. 22, 2025
In recent years, novel findings have progressively and promisingly supported the potential role of Artificial intelligence (AI) in transforming management various neoplasms, including hepatocellular carcinoma (HCC). HCC represents most common primary liver cancer. Alarmingly, incidence is dramatically increasing worldwide due to simultaneous “pandemic” spreading metabolic dysfunction-associated steatotic disease (MASLD). MASLD currently constitutes leading cause chronic hepatic damage (steatosis steatohepatitis), fibrosis, cirrhosis, configuring a scenario where an onset has been reported even early stage. On other hand, serious plague, significantly burdening outcomes hepatitis B (HBV) C (HCV) virus-infected patients. Despite progress this cancer, overall prognosis for advanced-stage patients continues be poor, suggesting absolute need develop personalized healthcare strategies further. “cold war”, machine learning techniques neural networks are emerging as weapons, able identify patterns biomarkers that would normally escaped human observation. Using advanced algorithms, AI can analyze large volumes clinical data medical images (including routinely obtained ultrasound data) with elevated accuracy, facilitating diagnosis, improving performance predictive models, supporting multidisciplinary (oncologist, gastroenterologist, surgeon, radiologist) team opting best “tailored” individual treatment. Additionally, contribute enhancing effectiveness metabolomics–radiomics-based promoting identification specific HCC-pathogenetic molecules new targets realizing therapeutic regimens. era precision medicine, integrating into routine practice appears promising frontier, opening avenues cancer research
Язык: Английский
Процитировано
3
Cells, Год журнала: 2025, Номер 14(3), С. 221 - 221
Опубликована: Фев. 4, 2025
Cigarette smoke (CS), an intricate blend comprising over 4000 compounds, induces abnormal cellular reactions that harm multiple tissues. Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic (CLD), encompassing non-alcoholic (NAFL), steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Recently, the term NAFLD has been changed to metabolic dysfunction-associated steatotic (MASLD), NASH renamed (MASH). A multitude of experiments have confirmed association between CS incidence progression MASLD. However, specific signaling pathways involved need be updated with new scientific discoveries. exposure can disrupt lipid metabolism, induce inflammation apoptosis, stimulate fibrosis through promote Currently, there no officially approved efficacious pharmaceutical intervention in clinical practice. Therefore, lifestyle modifications emerged as primary therapeutic approach for managing Smoking cessation application series natural ingredients shown ameliorate pathological changes induced by CS, potentially serving effective decelerating MASLD development. This article aims elucidate which smoking promotes MASLD, while summarizing reversal factors identified recent studies, thereby offering novel insights future research on treatment
Язык: Английский
Процитировано
3